Clinical distinction between medication-induced effects and weight-loss-associated changes remains challenging
GLP-1 receptors in the stomach and pylorus, when activated, slow the rate at which food moves from the stomach into the small intestine
Both are clinically effective
placebo, n=1 [6%]) had TEAEs of vitamin D deficiency that were refractory to clinically recommended vitamin supplementation
Adding creatine to an already sensitive stomach requires some thought
Use With Caution in Research Contexts Because Retatrutide interacts with GLP-1, GIP, and glucagon receptor pathways involved in metabolism, appetite regulation, gastric-emptying pathways, and glucose signaling, additional caution may be warranted in research models involving significant metabolic, gastrointestinal, pancreatic, or cardiometabolic conditions